Evidence map›Paper›PMID 22136831›Full record

Trial reportSurgery2011

Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.

Mio Kitano, Corina Millo, Reza Rahbari, Peter Herscovitch, Krisana Gesuwan, Richard C Webb, Aradhana M Venkatesan, Giao Q Phan, Marybeth S Hughes, Steven K Libutti and 3 more

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in Surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. The utility ofEuropean journal of radiology · 2019
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Mio KitanoEndocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, 10 Center Drive, Bethesda, MD 20892, USA.
Corina Millo
Reza Rahbari
Peter Herscovitch
Krisana Gesuwan
Richard C Webb
Aradhana M Venkatesan
Giao Q Phan
Marybeth S Hughes
Steven K Libutti
Naris Nilubol
William M Linehan
Electron Kebebew
National Institutes of Health · USYeshiva University · US

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZ01BC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZ01BC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Clinical Nursing and Data Management CoreZ01BC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$855k
Intramural NIH HHS Z01 BC011028Intramural NIH HHS Z01 BC011038Intramural NIH HHS Z01 BC011089Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011286NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

introductionThere are limited data on the utility of 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) and (18)F-2-deoxy-d-glucose ((18)F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of (18)F-DOPA and (18)F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL).

methodsWe studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), (18)F-FDG, and (18)F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results.

resultsIn sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on (18)F-DOPA and 45 of the 98 (46%) lesions were positive on (18)F-FDG. There were 13 (18)F-DOPA and 26 (18)F-FDG avid extrapancreatic lesions. One patient underwent resection of an (18)F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between (18)F-DOPA and (18)F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level.

conclusion(18)F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. (18)F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.

Indexed as

Fluorodeoxyglucose F18Magnetic Resonance ImagingRadiopharmaceuticalsAdolescentAdultAgedDopamineFemaleHumansMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsPositron-Emission TomographyProspective StudiesTomography, X-Ray Computed6-fluorodopamineDopamineFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID22136831
PMCPMC3293369
OpenAlexW2029593533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.